Capanu M - Search Results

1

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.

Maron SB, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, Do RKG, Paroder V, Pandit-Taskar N, Lewis JS, Biachi De Castria T, Sabwa S, Socolow F, Feder L, Thomas J, Schulze I, Kim K, Elzein A, Bojilova V, Zatzman M, Bhanot U, Nagy RJ, Lee J, Simmons M, Segal M, Ku GY, Ilson DH, Capanu M, Hechtman JF, Merghoub T, Shah S, Schultz N, Solit DB, Janjigian YY. Maron SB, et al. Among authors: capanu m. Clin Cancer Res. 2023 Sep 15;29(18):3633-3640. doi: 10.1158/1078-0432.CCR-22-3769. Clin Cancer Res. 2023. PMID: 37406106 Free PMC article. Clinical Trial.

2

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Shah MA, et al. Among authors: capanu m. J Clin Oncol. 2006 Nov 20;24(33):5201-6. doi: 10.1200/JCO.2006.08.0887. J Clin Oncol. 2006. PMID: 17114652 Clinical Trial.

3

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.

Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Ku GY, et al. Among authors: capanu m. Cancer Chemother Pharmacol. 2008 Oct;62(5):875-80. doi: 10.1007/s00280-008-0677-y. Epub 2008 Feb 13. Cancer Chemother Pharmacol. 2008. PMID: 18270704 Clinical Trial.

4

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. Shah MA, et al. Among authors: capanu m. Invest New Drugs. 2011 Dec;29(6):1475-81. doi: 10.1007/s10637-010-9474-7. Epub 2010 Jun 25. Invest New Drugs. 2011. PMID: 20574790 Clinical Trial.

5

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Shah MA, et al. Among authors: capanu m. J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189380 Free PMC article. Clinical Trial.

6

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. Ilson DH, et al. Among authors: capanu m. Cancer. 2011 Apr 1;117(7):1409-14. doi: 10.1002/cncr.25602. Epub 2010 Nov 8. Cancer. 2011. PMID: 21425140 Free PMC article. Clinical Trial.

7

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Ilson DH, et al. Among authors: capanu m. Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11. Cancer. 2012. PMID: 21990000 Free article. Clinical Trial.

8

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.

Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M, Saltz LB. Reidy-Lagunes DL, et al. Among authors: capanu m. Cancer. 2012 Oct 1;118(19):4795-800. doi: 10.1002/cncr.27459. Epub 2012 Mar 21. Cancer. 2012. PMID: 22437754 Free article. Clinical Trial.

9

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Janjigian YY, et al. Among authors: capanu m. Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f. Am J Clin Oncol. 2014. PMID: 23211227 Clinical Trial.

10

Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook AP, Abou-Alfa GK. Ang CS, et al. Among authors: capanu m. Gastrointest Cancer Res. 2013 Jan;6(1):3-9. Gastrointest Cancer Res. 2013. PMID: 23505572 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page